The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction

被引:16
作者
Duffy, Danielle [2 ]
Holmes, DaJuanicia N. [1 ]
Roe, Matthew T. [1 ]
Peterson, Eric D. [1 ]
机构
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27715 USA
[2] Thomas Jefferson Univ, Div Cardiol, Philadelphia, PA 19107 USA
关键词
ACUTE CORONARY SYNDROMES; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; HDL/HIGH TRIGLYCERIDES IMPACT; TREATMENT PANEL-III; HDL CHOLESTEROL; ATHEROTHROMBOSIS INTERVENTION; METABOLIC SYNDROME; STATIN THERAPY; EVENTS; TRIAL;
D O I
10.1016/j.ahj.2012.01.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Low serum high-density lipoprotein cholesterol (HDL-C) level is a potent risk factor for developing atherosclerosis, yet it is uncertain if HDL-C level at the time of non-ST-segment elevation myocardial infarction (NSTEMI) has downstream prognostic importance. Methods We evaluated 24,805 patients with NSTEMI aged >= 65 years enrolled at 434 Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) participating hospitals between February 15, 2003, and December 30, 2006, who had clinical data linked to Medicare files through December 31, 2008. Unadjusted and adjusted hazard ratios (HRs) were calculated to determine the association between HDL-C level at initial hospitalization and all-cause mortality, as well as a combined outcome of all-cause mortality or recurrent myocardial infarction (MI). Results Overall, 50% of patients had low HDL-C (<= 40 mg/dL) and 18% had very low HDL-C (<= 30 mg/dL). The rate of all-cause mortality was 39.5% during a median follow-up of 2.9 years; death or recurrent MI occurred in 43% in this older population with NSTEMI. Compared with patients who had normal HDL-C, those with very low HDL-C had a modest but significantly higher long-term mortality risk (adjusted HR 1.12, 95% CI 1.06-1.19, P = .0001). The adjusted HR for mortality or recurrent MI was the same. When modeled as a continuous variable, every 5-mg/dL decrement in HDL-C below 40 mg/dL was associated with a 5% increased risk of long-term mortality, as well as the combined end point. Conclusions Older patients with NSTEMI with low levels of HDL-C are at increased risk for downstream mortality or recurrent MI. Future studies are needed to evaluate strategies to reduce this residual risk. (Am Heart J 2012;163:705-13.)
引用
收藏
页码:705 / 713
页数:9
相关论文
共 22 条
[1]  
[Anonymous], 2001, JAMA, V285, P2486
[2]   HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J].
Barter, Philip ;
Gotto, Antonio M. ;
LaRosa, John C. ;
Maroni, Jaman ;
Szarek, Michael ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Bittner, Vera ;
Fruchart, Jean-Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) :1301-1310
[3]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[4]  
Boden WE., 2000, The American Journal of Cardiology, V86, P19, DOI DOI 10.1016/S0002-9149(00)01464-8
[5]   Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].
Boden, William E. ;
Probstfield, Jeffrey L. ;
Anderson, Todd ;
Chaitman, Bernard R. ;
Desvignes-Nickens, Patrice ;
Koprowicz, Kent ;
McBride, Ruth ;
Teo, Koon ;
Weintraub, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267
[6]   The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) [J].
Brown, B. Gregory ;
Boden, William E. ;
Probstfield, Jeffrey R. ;
McBride, Ruth ;
Anderson, Todd ;
Chaitman, Bernard ;
Marcovina, Santica ;
Weintraub, William ;
Zhao, Xue-Qiao ;
Teo, Koon ;
Kaiser, Judith ;
Desvignes-Nickens, Patrice ;
Fleg, Jerome L. ;
McGovern, Mark E. ;
Stolzenbach, James C. ;
Padley, Robert J. .
AMERICAN HEART JOURNAL, 2011, 161 (03) :471-+
[7]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[8]   Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial [J].
de Lemos, JA ;
Blazing, MA ;
Wiviott, SD ;
Lewis, EF ;
Fox, KAA ;
White, HD ;
Rouleau, JL ;
Pedersen, TR ;
Gardner, LH ;
Mukherjee, R ;
Ramsey, KE ;
Palmisano, J ;
Bilheimer, DW ;
Pfeffer, MA ;
Califf, RM ;
Braunwald, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (11) :1307-1316
[9]   Update on strategies to increase HDL quantity and function [J].
Duffy, Danielle ;
Rader, Daniel J. .
NATURE REVIEWS CARDIOLOGY, 2009, 6 (07) :455-463
[10]   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].
Grundy, SM ;
Cleeman, JI ;
Merz, CNB ;
Brewer, HB ;
Clark, LT ;
Hunninghake, DB ;
Pasternak, RC ;
Smith, SC ;
Stone, NJ .
CIRCULATION, 2004, 110 (02) :227-239